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We studied preexisting immunity to pandemic (H1N1) 
2009 virus in persons in Taiwan. A total of 18 (36%) of 50 
elderly adults in Taiwan born before 1935 had protective an-
tibodies against currently circulating pandemic (H1N1) 2009 
virus. Seasonal inﬂ  uenza vaccines induced antibodies that 
did not protect against pandemic (H1N1) 2009 virus.
A
s experts were predicting and warning of a new inﬂ  u-
enza pandemic (1), an inﬂ  uenza epidemic occurred 
in April 2009 in the United States and Mexico and result-
ed in a pandemic 2 months later. The etiologic agent was 
identiﬁ  ed as pandemic (H1N1) 2009 virus. Worldwide, 
most patients infected with this virus were <25 years of 
age, and one third of serious cases were in persons <50 
years of age (2,3).
The hemagglutinin gene of pandemic (H1N1) 2009 
virus was shown to be derived from the 1918 swine inﬂ  u-
enza virus and contained other genes from human, avian, 
and swine inﬂ  uenza viruses from Eurasia (2). In this study, 
we evaluated levels of preexisting cross-reactive antibodies 
against pandemic (H1N1) 2009 virus produced after previ-
ous infection in children and adults in Taiwan. We also ex-
amined serologic changes after vaccination with seasonal 
nonadjuvanted inﬂ  uenza vaccine.
The Study
Serum samples were obtained during a nationwide in-
ﬂ  uenza vaccine serologic study in Taiwan that started in 
2006. Children (<5 years of age), adults (20–49 years of 
age), older adults (50–74 years of age), and elderly adults 
(>75 years of age) were recruited. Serum samples were ob-
tained immediately before and 3 weeks after intramuscular 
injection with 1 dose of nonadjuvanted, trivalent, inactivat-
ed inﬂ  uenza vaccine formulated for the 2008–09 Northern 
Hemisphere winter season (samples were obtained from 
some participants >75 years of age before and after receiv-
ing 1 dose of the vaccine formulated for the 2007–08 win-
ter season).
Microneutralization (MN) and hemagglutination inhi-
bition (HI) assays were performed according to the World 
Health Organization Manual on Animal Inﬂ  uenza Diag-
nosis and Surveillance (4). Using these assays with 0.75% 
guinea pig erythrocytes, we assayed samples for antibodies 
against A/California/07/2009 (H1N1) virus. Only prevac-
cination HI assays were conducted for children.
The seroprotection rate was deﬁ  ned as the percentage 
of serum titers >40 by HI or titers >160 by MN. The sero-
conversion rate was deﬁ  ned as the percentage of vaccine 
recipients whose serum HI titers or MN titers increased by 
at least 4-fold after vaccination. A p value <0.05 was con-
sidered signiﬁ  cant. Stata software version 8.2 (StataCorp 
LP, College Station, TX, USA) was used for analysis.
A total of 176 participants (40 children, 36 adults, 50 
older adults, and 50 elderly adults) were enrolled (Table). 
Few or no preexisting cross-reactive antibodies against 
pandemic (H1N1) 2009 virus were detected by HI assay in 
samples from children (prevaccination seroprotection rate 
0%). As age increased, prevaccination seroprotection rates 
became higher for HI and MN assays. After vaccination, 
seroprotection rates and geometric mean titers measured by 
HI assay were essentially unchanged but increased signiﬁ  -
cantly in the 3 adult groups when measured by MN assay 
(p<0.05). Seroconversion rates among all participants were 
low. Analyses of relationships between age and antibody 
titers are shown in the Figure.
We log-transformed MN and HI titers, and used mul-
tiple regression, controlling for age groups to analyze the 
correlation between age and titer. Doubling of HI titers 
corresponded to an estimated 75% (p<0.01) increment in 
MN titers adjusted by age. When adjusted for HI titers, MN 
titers in older adults and elderly adults were 1.74× (p<0.01) 
and 2× (p<0.01), respectively, those in adults. Older adults 
and elderly adults with the same HI titers were more likely 
to have higher MN titers than adults (p<0.05, by ordinal 
logistic regression analysis).
Conclusions
We found that children in Taiwan had few or no cross-
reactive antibodies against pandemic (H1N1) 2009 virus. 
However, adults had some preexisting immunity to this vi-
rus. A major ﬁ  nding was that 18 (36%) of 50 elderly adults 
in Taiwan born before 1935 had protective antibodies 
against currently circulating pandemic (H1N1) 2009 virus. 
The seroprotection rate may be 50% in persons >80 years 
of age.
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The MN assay showed that seasonal inﬂ  uenza vac-
cines generated large increases in geometric mean titers 
in vaccinees in all age groups. We suggest that seasonal 
inﬂ  uenza vaccines are likely to elicit a certain degree of 
cross-reactive antibodies against pandemic (H1N1) 2009 
virus and may provide some level of protection. In persons 
who had no preexisting seroprotective titers against pan-
demic (H1N1) 2009 virus, the cross-reactivity produced 
was not sufﬁ  cient to prevent disease; however, it may pro-
tect against the severe forms of the disease.
Hancock et al. (5) reported that only 4% of persons in 
the United State born after 1980 had preexisting cross-re-
active antibodies against pandemic (H1N1) 2009 virus, and 
that 34% of persons born before 1950 had neutralizing ti-
ters >80. However, Itoh et al. (6) reported that blood donors 
from Japan who were born after 1920 had almost no appre-
ciable neutralizing antibodies against this virus. Because 
the hemagglutinin gene of pandemic (H1N1) 2009 virus is 
similar to that of viruses that circulated in humans during 
1918–1957 (7), Itoh et al. suggested that pandemic (H1N1) 
2009 virus is antigenically divergent from human inﬂ  uenza 
viruses (H1N1) that circulated during the 1920s–1950s.
Our results are consistent with those of Hancock et al. 
(5), who suggested that human inﬂ  uenza virus (H1N1) cir-
culating in Taiwan after 1920 resembled the 1918 pandemic 
virus (H1N1) and pandemic (H1N1) 2009 virus and could 
lead to cross-protection against the current virus. Further-
more, unlike the situation in the United States, there was no 
program for vaccination against the 1976 swine inﬂ  uenza 
virus (A/NJ/76) in Taiwan. However, a similar virus was 
present in Taiwan before 1957. The results of our study 
also explain why only 7% of patients hospitalized for pan-
demic (H1N1) 2009 virus in Taiwan were >65 years of age 
(8). Similar epidemiologic observations have been reported 
in the United States (3) and New Zealand (9).
Whether elderly persons still have cross-reactivity 
several decades after exposure to 1918 (H1N1) virus is 
unknown. The concept of original antigenic sin is a prob-
able explanation. Original antigenic sin has been described 
in relation to inﬂ  uenza virus, dengue virus, HIV, and sev-
eral other viruses (10–12). For persons >65 years of age, 
the 1918 (H1N1) virus is likely the ﬁ  rst inﬂ  uenza virus 
to which they were exposed, and their antibody response 
should have increased in subsequent years.
Regression analysis showed that older persons with 
high HI titers were more likely than younger adults to have 
higher MN titers. Because the HI assay detects only anti-
bodies against hemagglutinin, the MN assay provides more 
information about the level of protective antibodies against 
inﬂ  uenza viruses. As a person ages, production of antibod-
ies against hemagglutinin or other components of inﬂ  uenza 
virus should protect against potential infections. Although 
a titer of 40 by HI is accepted as a cutoff value for seropro-
tection, a consensus for protective titers by MN is lacking 
(5,13). We suggest that MN is probably more sensitive than 
HI for evaluating neutralizing antibodies against pandemic 
(H1N1) 2009 virus.
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Table. Geometric mean titers of antibodies and rates of seroprotection against pandemic (H1N1) 2009 virus before and after seasonal
influenza vaccination, by age, Taiwan, 2007–2008*
Group, age, y 
Prevaccination GMT 
(95% CI) 
Prevaccination
seroprotection
rate, % 
Postvaccination GMT 
(95% CI) 
Postvaccination
seroprotection
rate, %  p value
Children <5, n = 40) 
 HI  10.4  (9.9–10.9)  0 ND  ND  ND 
Adults 20–49, n = 36 
  HI  12.1 (10.7–13.7)  2.8 12.1 (10.7–13.7)  2.80 NS
MN 26.3 (20.9–32.8) 0 31.7 (25.0–40.3) 0 <0.05
Older adults 50–74, n = 50 
  HI  16.7 (14.2–19.7) 16 16.7 (14.2–19.7) 16 NS
  MN  59.0 (47.7–72.8) 20 74.6 (60.0–92.9) 32 <0.05
Elderly adults >75, n = 50 
  HI  22.7 (19.5–26.4) 36 23.3 (19.8–27.4) 38 0.159 
  MN  85.7 (70.8–103.9)  32 107 (89.2–128.5)  44 <0.05
*GMT, geometric mean titer; CI, confidence interval; HI, hemagglutination inhibition; ND, not done; NS, not significant. MN, microneutralization. Mean r
SD ages for the 4 groups were 20.0 ± 11.3 mo for children, 34.5 ± 7.5 y for adults, 65 ± 6 y for older adults, and 79 ± 3.3 y for elderly adults. 
Figure. Seroprotection rates determined by hemagglutination 
inhibition (HI) assay (white bars) or microneutralization (MN) assay 
(gray bars) and geometric mean titer (GMT) of antibodies against 
pandemic (H1N1) 2009 virus in each 10-year age cohort, Taiwan, 
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